Nifty
:
22620.40
Sensex
:
73730.16
50.05 (0.22%)
-609.28 (-0.82%)
Nifty
Sensex
:
:
22620.40
73730.16
50.05 (0.22%)
-609.28 (-0.82%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
67/99

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
1506.55
26-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1531.00
  •  1532.00
  •  1500.05
  •  1520.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1794350
  •  27068.18
  •  1638.85
  •  922.45

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 360,919.96
  • 40.52
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 355,185.85
  • 0.76%
  • 5.78

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 2.09%
  • 5.44%
  • FII
  • DII
  • Others
  • 17.72%
  • 17.38%
  • 2.89%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.56
  • 8.59
  • 9.42

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.12
  • 12.81
  • 6.24

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.49
  • 26.15
  • 42.97

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 35.10
  • 35.13
  • 38.21

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.77
  • 3.70
  • 4.41

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.48
  • 18.09
  • 20.06

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
12,380.70
11,240.97
10.14%
12,192.41
10,952.28
11.32%
11,940.84
10,761.76
10.96%
10,930.67
9,446.76
15.71%
Expenses
9,028.43
8,237.25
9.60%
9,013.03
7,995.73
12.72%
8,611.11
8,023.04
7.33%
8,128.54
7,267.41
11.85%
EBITDA
3,352.27
3,003.72
11.60%
3,179.38
2,956.55
7.54%
3,329.73
2,738.72
21.58%
2,802.13
2,179.35
28.58%
EBIDTM
27.08%
26.72%
26.08%
26.99%
27.89%
25.45%
25.64%
23.07%
Other Income
374.76
173.88
115.53%
293.61
85.22
244.53%
206.48
147.81
39.69%
373.28
274.61
35.93%
Interest
34.73
46.18
-24.79%
49.29
19.39
154.20%
80.88
13.69
490.80%
92.74
37.34
148.37%
Depreciation
622.14
659.95
-5.73%
632.82
609.95
3.75%
651.32
588.00
10.77%
671.53
556.47
20.68%
PBT
3,000.35
2,471.47
21.40%
2,790.88
2,412.43
15.69%
2,481.14
2,284.84
8.59%
2,239.69
-2,075.60
-
Tax
432.32
283.43
52.53%
390.10
152.26
156.21%
468.10
188.99
147.69%
222.91
146.76
51.89%
PAT
2,568.03
2,188.04
17.37%
2,400.78
2,260.17
6.22%
2,013.04
2,095.85
-3.95%
2,016.78
-2,222.36
-
PATM
20.74%
19.46%
19.69%
20.64%
16.86%
19.48%
18.45%
-23.53%
EPS
10.52
9.03
16.50%
9.90
9.43
4.98%
8.43
8.59
-1.86%
8.27
-9.49
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
47,444.62
43,885.68
38,654.49
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
Net Sales Growth
11.89%
13.53%
15.39%
2.01%
12.98%
10.03%
-15.63%
11.38%
2.62%
70.34%
 
Cost Of Goods Sold
10,532.42
10,662.16
10,351.54
8,690.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
2,777.68
Gross Profit
36,912.20
33,223.52
28,302.95
24,808.06
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
13,302.68
GP Margin
77.80%
75.70%
73.22%
74.06%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
82.73%
Total Expenditure
34,781.11
32,424.22
28,772.68
25,030.42
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
Power & Fuel Cost
-
830.05
702.78
627.09
621.89
613.60
559.97
525.09
545.44
560.77
232.41
% Of Sales
-
1.89%
1.82%
1.87%
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
1.45%
Employee Cost
-
8,296.03
7,300.83
6,862.23
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
% Of Sales
-
18.90%
18.89%
20.49%
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
12.90%
Manufacturing Exp.
-
1,936.77
1,880.71
1,723.78
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
815.49
% Of Sales
-
4.41%
4.87%
5.15%
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
5.07%
General & Admin Exp.
-
4,256.12
3,270.55
3,179.45
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
978.48
% Of Sales
-
9.70%
8.46%
9.49%
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
6.08%
Selling & Distn. Exp.
-
5,226.24
4,096.33
3,103.96
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
% Of Sales
-
11.91%
10.60%
9.27%
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
8.67%
Miscellaneous Exp.
-
1,216.85
1,169.94
843.83
963.29
1,107.57
1,047.60
1,106.04
1,824.56
1,254.03
1,394.78
% Of Sales
-
2.77%
3.03%
2.52%
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
5.27%
EBITDA
12,663.51
11,461.46
9,881.81
8,467.72
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
EBITDA Margin
26.69%
26.12%
25.56%
25.28%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
43.28%
Other Income
1,248.13
819.85
1,437.42
859.17
651.59
1,059.44
912.08
1,030.20
658.25
637.89
592.59
Interest
257.64
172.00
127.35
141.43
302.73
555.25
517.57
399.80
523.24
578.99
44.19
Depreciation
2,577.81
2,529.43
2,143.74
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
409.23
PBT
10,512.06
9,579.88
9,048.14
7,105.51
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
Tax
1,513.43
847.59
1,075.50
514.69
822.80
600.88
911.04
1,211.57
913.77
914.69
702.17
Tax Rate
14.40%
9.01%
24.00%
18.39%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
15.33%
PAT
8,998.63
8,521.48
3,289.27
2,916.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
3,141.47
PAT before Minority Interest
8,970.71
8,560.84
3,405.82
2,284.68
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
3,879.00
Minority Interest
-27.92
-39.36
-116.55
631.47
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
-737.53
PAT Margin
18.97%
19.42%
8.51%
8.71%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
19.54%
PAT Growth
108.22%
159.07%
12.79%
-22.85%
41.73%
25.73%
-69.50%
53.04%
-0.17%
44.90%
 
EPS
37.51
35.52
13.71
12.15
15.75
11.12
8.84
28.99
18.94
18.97
13.09

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
55,995.38
48,011.22
46,462.78
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
18,524.95
Share Capital
239.93
239.93
239.93
239.93
239.93
239.93
239.93
240.66
207.12
207.12
Total Reserves
55,755.45
47,771.29
46,222.85
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
18,317.83
Non-Current Liabilities
-1,643.12
-1,316.37
-1,515.17
246.05
76.72
46.43
599.87
2,169.59
2,335.46
1,748.41
Secured Loans
0.00
0.00
7.83
6.18
109.47
217.69
185.59
7.73
40.69
43.76
Unsecured Loans
0.00
229.92
646.88
2,022.74
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
4.91
Long Term Provisions
342.91
369.07
327.12
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
2,601.62
Current Liabilities
19,906.38
17,208.45
16,145.63
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
Trade Payables
5,681.52
4,489.76
3,973.66
3,583.64
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
Other Current Liabilities
2,603.51
2,926.73
4,965.34
2,535.02
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
260.41
Short Term Borrowings
5,958.26
468.52
2,444.90
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
Short Term Provisions
5,663.09
9,323.44
4,761.73
4,038.39
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
Total Liabilities
77,578.73
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
Net Block
24,420.12
22,665.16
21,552.98
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
Gross Block
43,454.63
38,707.36
35,578.99
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
10,485.12
Accumulated Depreciation
19,034.51
16,042.20
14,026.01
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
7,724.42
3,667.84
Non Current Assets
37,696.01
32,093.59
33,668.21
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
Capital Work in Progress
4,973.16
1,286.80
1,566.83
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
841.54
Non Current Investment
5,457.48
5,214.65
6,482.39
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
787.56
Long Term Loans & Adv.
2,752.12
2,880.86
4,061.34
4,104.48
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
1,016.98
Other Non Current Assets
93.13
46.12
4.67
5.53
21.96
50.21
682.18
953.34
103.94
34.20
Current Assets
39,861.94
34,864.60
30,442.08
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
Current Investments
9,372.61
7,633.94
3,130.06
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
1,998.46
Inventories
10,513.05
8,925.13
8,997.02
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
Sundry Debtors
11,438.51
10,484.59
9,061.40
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
Cash & Bank
5,770.29
5,033.35
6,445.51
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
Other Current Assets
2,767.48
775.01
1,319.11
1,541.48
3,072.69
2,919.93
3,546.51
2,847.64
5,026.16
3,774.42
Short Term Loans & Adv.
2,021.57
2,012.58
1,488.98
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
Net Current Assets
19,955.56
17,656.15
14,296.45
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
Total Assets
77,557.95
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
4,959.33
8,984.54
6,170.37
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
PBT
9,408.43
4,481.32
2,799.37
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
Adjustment
2,722.56
1,974.95
1,809.85
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
-40.15
Changes in Working Capital
-5,661.82
1,559.05
2,564.09
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
207.10
Cash after chg. in Working capital
6,469.17
8,015.32
7,173.31
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,509.84
969.22
-1,002.94
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-7,943.68
-5,724.74
536.22
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
Net Fixed Assets
-573.97
-1,120.95
-8,061.35
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
-380.81
Net Investments
2,932.47
-11.67
1,824.52
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
Others
-10,302.18
-4,592.12
6,773.05
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
712.24
Cash from Financing Activity
2,376.07
-5,193.46
-5,980.48
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
Net Cash Inflow / Outflow
-608.28
-1,933.66
726.11
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
2,099.01
Opening Cash & Equivalents
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
Closing Cash & Equivalent
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
233.38
200.11
193.65
188.66
172.59
159.69
152.70
137.03
123.49
89.44
ROA
11.85%
5.20%
3.54%
6.58%
5.17%
4.24%
0.00%
11.39%
14.60%
16.21%
ROE
16.46%
7.21%
4.98%
9.66%
8.05%
6.85%
0.00%
19.32%
24.89%
23.15%
ROCE
17.24%
9.28%
5.68%
10.07%
8.68%
8.40%
0.00%
18.64%
25.06%
25.46%
Fixed Asset Turnover
1.81
1.81
1.74
1.78
1.92
1.99
1.29
1.34
1.79
1.70
Receivable days
53.89
53.09
54.88
56.22
54.10
53.53
83.25
76.12
48.20
51.72
Inventory Days
47.78
48.68
50.10
48.40
47.84
48.88
78.98
77.46
57.99
63.92
Payable days
174.10
149.21
158.71
152.86
77.81
90.19
85.47
75.24
52.05
56.33
Cash Conversion Cycle
-72.43
-47.44
-53.73
-48.24
24.13
12.23
76.75
78.34
54.14
59.31
Total Debt/Equity
0.11
0.02
0.08
0.18
0.25
0.27
0.27
0.26
0.35
0.14
Interest Cover
55.70
36.19
20.79
17.55
7.86
7.72
23.63
13.56
12.06
104.67

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • USFDA issues OAI status to Sun Pharmaceutical Industries’ Dadra facility
    12th Apr 2024, 11:20 AM

    USFDA conducted an inspection at Company’s Dadra facility from December 4, 2023 to December 15, 2023

    Read More
  • Sun Pharma’s arm recalls around 55,000 bottles of generic drug from US market
    11th Mar 2024, 11:51 AM

    The New Jersey-based unit of the Mumbai-based drug major is recalling Febuxostat Tablets in 40 mg and 80 mg strengths

    Read More
  • Sun Pharmaceutical to acquire 16.33% stake in Surgimatix
    21st Feb 2024, 12:00 PM

    The cost of acquisition is around $3.05 million

    Read More
  • Sun Pharma included in S&P Global Sustainability Yearbook 2024
    12th Feb 2024, 11:42 AM

    This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance principles through focused initiatives across its businesses

    Read More
  • Sun Pharmaceutical Industries’ arm incorporates wholly-owned subsidiary
    6th Feb 2024, 10:15 AM

    Taro Pharma Corporation is set up as an entity separate from Alchemee LLC, a subsidiary of Taro Israel, to help Alchemee LLC with selling its Proactiv skincare products on e-commerce marketplace in USA

    Read More
  • Sun Pharmaceutical Industries reports 17% rise in Q3 consolidated net profit
    31st Jan 2024, 17:17 PM

    Total consolidated income of the company increased by 10.65% at Rs 12630.90 crore for Q3FY24

    Read More
  • Sun Pharma Inds. - Quarterly Results
    31st Jan 2024, 14:13 PM

    Read More
  • Sun Pharmaceutical to acquire remaining stake in Taro Pharmaceutical Industries
    18th Jan 2024, 14:14 PM

    Sun Pharmaceutical will acquire 8,086,818 shares constituting 21.52% of the total outstanding shares of Taro for a cash consideration of $43 per share amounting to Rs 2,891.76 crore

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.